Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scancell HoldingsLSE:SCLP -1.02% EV-to-OCF is -16.76 as of Sep. 20, 2026. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Scancell Holdings ranks better than 79.3% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Scancell Holdings's Enterprise Value is £139.88 Mil.
Scancell Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Oct. 2025 was £-8.35 Mil. Therefore, Scancell Holdings's EV-to-OCF for today is -16.76.
The historical rank and industry rank for Scancell Holdings's EV-to-OCF or its related term are showing as below:
LSE:SCLP'
s EV-to-OCF Range Over the Past 10 Years
Min: -36.14 Med: -14.2 Max: -7.87
Current: -16.8
During the past 13 years, the highest EV-to-OCF of Scancell Holdings was -7.87. The lowest was -36.14. And the median was -14.20.
LSE:SCLP's EV-to-OCF is ranked better than 79.3% of 1406
companies
in the Biotechnology industry
Industry Median: -3.37
vs LSE:SCLP: -16.80
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scancell Holdings's PE Ratio (TTM) for today is calculated as:
Scancell Holdings's share price for today is £0.0975.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2025 was £-0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Scancell Holdings EV-to-OCF Related Terms
Scancell Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SCLP vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Scancell Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's EV-to-OCF falls into.
Scancell Holdings's current Enterprise Value is £139.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Oct. 2025 was £-8.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (LSE:SCLP) has a EV-to-OCF of -16.76 as of Sep. 20, 2026. According to the industry distribution chart, Scancell Holdings ranks #291 out of 1406 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Scancell Holdings' EV-to-OCF too high?
Scancell Holdings' current EV-to-OCF is -16.76. Based on the distribution chart, Scancell Holdings ranks #291 out of 1406 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Scancell Holdings' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #291 out of 1406 companies for EV-to-OCF. This places Scancell Holdings in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Scancell Holdings's current EV-to-OCF is -16.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (LSE:SCLP) has a current EV-to-OCF of -16.76. The current EV-to-OCF is -16.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Scancell Holdings (LSE:SCLP), the current EV-to-OCF is -16.76 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SCLP has been successfully added to your 
